+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Analysis of HER2 by chromogenic in situ hybridization and immunohistochemistry in lymph node-negative breast carcinoma: Prognostic relevance



Analysis of HER2 by chromogenic in situ hybridization and immunohistochemistry in lymph node-negative breast carcinoma: Prognostic relevance



Human Pathology 38(1): 26-34



In patients with lymph node-negative breast carcinoma (LNNBC), the prevalence of HER2 overexpression and gene amplification and their prognostic value have not been extensively evaluated. We examined 162 patients with LNNBC with complete follow-up. Immunohistochemistry (IHC) for HER2, Ki67, and p53 was performed. HER2 gene status was analyzed by chromogenic in situ hybridization (CISH) and discordant cases by fluorescence in situ hybridization. HER2 overexpression was seen in 24.7% of cases (40/162) and amplification by CISH in 17.6% (28/159). Agreement between IHC and CISH was achieved in 147 (92.5%) cases. Amplification was seen in 21 (100%) of 21 (3+), 6 (35.3%) of 17 (2+), and 1 (0.6%) of 121 (0-1+) tumors. Fluorescence in situ hybridization detected 3 (1.8%) additional cases. HER2 overexpression and amplification were present in tumors of high grade, with necrosis and lymph-vascular invasion (LVI) (all P < .027). In addition, amplified tumors showed Ki67 of more than 20% and p53 overexpression (P < .05). By univariate analysis, shorter disease-free survival (DFS) and overall survival (OS) were seen for patients with tumors showing HER2 amplification, LVI, and Ki67 of more than 20% (P < .05) (Kaplan-Meier). However, the multivariate analysis (Cox regression) demonstrated only Ki67 as an independent prognostic factor for both DFS (P = .017) and OS (P = .010), and as a trend for HER2 gene status (OS, P = .087) and LVI (DFS, P = .11; OS, P = .063). We conclude that IHC is a reliable method for detecting HER2 expression that can be complemented by CISH in nondefinitive cases (2+). Moreover, CISH is a valuable tool for the assessment of HER2 gene status with potential prognostic value and, therefore, in clinical decision making for treatment of high-risk LNNBC.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 012943991

Download citation: RISBibTeXText

PMID: 17056098

DOI: 10.1016/j.humpath.2006.07.013


Related references

Analysis of HER2 gene amplification and its protein expression in 165 cases of breast carcinoma: comparison of chromogenic in-situ hybridization and immunohistochemistry. Zhonghua Bing Li Xue Za Zhi 36(7): 457-460, 2007

Role of chromogenic in situ hybridization (CISH) in the evaluation of HER2 status in breast carcinoma: comparison with immunohistochemistry and FISH. International Journal of Surgical Pathology 13(4): 343-351, 2005

Role of Chromogenic in Situ Hybridization (Cishtm) in the Evaluation of Her2 Status in Breast Carcinoma: Comparison with Immunohistochemistry and Fish. International Journal of Surgical Pathology 13(4): 343-351, 2005

HER2 expression and its prognostic implication in lymph node negative breast carcinoma: a Meta-analysis. Zhonghua Bing Li Xue Za Zhi 34(3): 140-146, 2005

Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Pathology International 62(11): 728-734, 2012

HER2 positivity in breast carcinoma: a comparison of chromogenic in situ hybridization with fluorescence in situ hybridization in tissue microarrays, with targeted evaluation of intratumoral heterogeneity by in situ hybridization. Applied Immunohistochemistry & Molecular Morphology 13(2): 194-200, 2005

Evaluating HER2 Gene Amplification Using Chromogenic In Situ Hybridization (CISH) Method In Comparison To Immunohistochemistry Method in Breast Carcinoma. Open Access Macedonian Journal of Medical Sciences 6(11): 1977-1981, 2018

Negative HER2/neu amplification using immunohistochemistry and chromogenic in situ hybridization techniques in skin melanoma cases. Asian Pacific Journal of Cancer Prevention 16(2): 421-425, 2015

HER2 amplification through CISH -chromogenic hybridization in situ- on breast cancer Her 2 2+ by immunohistochemistry -ICH. Journal of Clinical Oncology 26(15_Suppl): 22147-22147, 2016

Chromogenic in situ hybridization for Her-2/neu-oncogene in breast cancer: comparison of a new dual-colour chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization. Histopathology 55(6): 716-723, 2009

Comparision of HER2/neu oncogene detected by chromogenic in-situ hybridization and immunohistochemistry in breast cancer. Zhonghua Bing Li Xue Za Zhi 35(10): 580-583, 2006

Evaluation of HER2 gene status in breast cancer by chromogenic in situ hybridization: comparison with immunohistochemistry. Anticancer Research 25(2a): 939-946, 2005

Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization. Pathology International 58(1): 17-25, 2008

Comparison of dual-colour chromogenic in-situ hybridization and fluorescence in-situ hybridization in the assessment of HER2 gene amplification in breast carcinoma. Histopathology 58(2): 319-321, 2011

Comparing fluorescence in situ hybridization and chromogenic in situ hybridization methods to determine the HER2/neu status in primary breast carcinoma using tissue microarray. Modern Pathology 16(9): 937-943, 2003